Researchers from University College London (UCL) in the UK found that people who used lansoprazole, as opposed to similar drugs omeprazole or pantoprazole, were a third less likely to develop TB.
In 2016, 10.4 million people fell ill with tuberculosis and it is in the top ten causes of death globally, killing more people than any other infectious disease, they said.
"It would be a major breakthrough to find a new drug with useful activity against Mycobacterium tuberculosis and a favourable side effect profile - particularly a drug like lansoprazole, which costs pennies," said Tom Yates from UCL Institute for Global Health.
"While it is too early to say whether lansoprazole can be used to treat TB, we think there is a strong case for further study," said Yates, first author the study published in the journal PLOS Medicine.
Also Read
The researchers analysed data that had been routinely collected by general practices and hospitals in the UK and compared the incidence of TB in people taking lansoprazole with that in people taking omeprazole or pantoprazole.
The research was prompted by a laboratory study, described in a 2015 paper in the journal Nature Communications, finding that lansoprazole was effective at killing Mycobacterium tuberculosis, while other drugs in the same class had no effect.
The findings show that, among people using lansoprazole, there were 10 cases of TB per 100,000 person years compared to 15.3 cases among those using omeprazole or pantoprazole.
In many parts of the world, particularly in Southern Africa, Eastern Europe and Central Asia drug resistant tuberculosis is a major problem, researchers said.
Many of the existing drugs used to treat drug resistant TB have unacceptable side effects, they said.
"We know that medications can have unintended effects; often these are harmful, but occasionally we also find unexpected benefits that may offer new hope for difficult to treat diseases," said Ian Douglas, Associate Professor at the London School of Hygiene & Tropical Medicine in the UK.
Disclaimer: No Business Standard Journalist was involved in creation of this content